Enhanced oral and pulmonary delivery of biomacromolecules via amplified transporter targeting
Journal of Controlled Release · 2024
DOI: 10.1016/j.jconrel.2024.04.026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024. Verfasst von Xin Xiao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-So…. Hauptthemen laut MEDLINE: Colforsin, Nanoparticles. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 62 Literaturangaben.
Abstract (Originalsprache)
Ligand-modified nanocarriers can promote oral or inhalative administration of macromolecular drugs across the intestinal or pulmonary mucosa. However, enhancing the unidirectional transport of the nanocarriers through "apical uptake→intracellular transport→basolateral exocytosis" route remains a hot topic and challenge in current research. Forskolin is a naturally occurring diterpenoid compound extracted from the roots of C. forskohlii. In our studies, we found that forskolin could increase the transcellular transport of butyrate-modified nanoparticles by 1.67-fold and 1.20-fold in Caco-2 intestinal epithelial cell models and Calu-3 lung epithelial cell models, respectively. Further mechanistic studies revealed that forskolin, on the one hand, promoted the cellular uptake of butyrate-modified nanoparticles by upregulating the expression of monocarboxylic acid transporter-1 (MCT-1) on the apical membrane. On the other hand, forskolin facilitated the binding of MCT-1 to caveolae, thereby mediating butyrate-modified nanoparticles hijacking caveolae to promote the basolateral exocytosis of butyrate-modified nanoparticles. Studies in normal mice model showed that forskolin could promote the transmucosal absorption of butyrate-modified nanoparticles by >2-fold, regardless of oral or inhalative administration. Using semaglutide as the model drug, both oral and inhalation delivery approaches demonstrated significant hypoglycemic effects in type 2 diabetes mice model, in which inhalative administration was more effective than oral administration. This study optimized the strategies aimed at enhancing the transmucosal absorption of ligand-modified nanocarriers in the intestinal or pulmonary mucosa.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial T…
- School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, 85 Park Road, Grafton, Auckland 1023, New Zealand.
Zitieren
APA
Xiao, X., Zhang, L., Ni, M., Liu, X., Xing, L., Wu, L., Zhou, Z., Li, L., Wen, J., & Huang, Y. (2024). Enhanced oral and pulmonary delivery of biomacromolecules via amplified transporter targeting. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2024.04.026
Vancouver
Xiao X, Zhang L, Ni M, Liu X, Xing L, Wu L, et al. Enhanced oral and pulmonary delivery of biomacromolecules via amplified transporter targeting. Journal of Controlled Release. 2024. doi:10.1016/j.jconrel.2024.04.026
BibTeX
@article{Xiao2024,
author = {Xiao, Xin and Zhang, Lie and Ni, Mingjie and Liu, Xi and Xing, Liyun and Wu, Licheng and Zhou, Zhou and Li, Lian and Wen, Jingyuan and Huang, Yuan},
title = {Enhanced oral and pulmonary delivery of biomacromolecules via amplified transporter targeting},
journal = {Journal of Controlled Release},
year = {2024},
doi = {10.1016/j.jconrel.2024.04.026}
}
EUVIMED